SCHEMBL23833533

SCHEMBL23833533

Cc1cc(NN)ncc1N1CCCC1=O

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.51
▸ LMNA P02545 2/20 0.42
▸ L3MBTL1 Q9Y468 3/20 0.40
▸ CYP2C9 P11712 2/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ AKR1C3 P42330 1/20 0.38
▸ PKM P14618 3/20 0.38
▸ TP53 P04637 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ FFAR1 O14842 2/20 0.36
▸ FFAR4 Q5NUL3 2/20 0.36
▸ PCSK9 Q8NBP7 1/20 0.35
▸ ALOX5AP P20292 1/20 0.35
▸ FEN1 P39748 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ FLT3 P36888 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30094589 1.00 HSD17B10 (0.51) HSD17B10LMNAL3MBTL1CYP2C9CYP3A4
SCHEMBL23833638 0.78 HSD17B10 (0.51) HSD17B10LMNAL3MBTL1CYP2C9CYP3A4
SCHEMBL30094610 0.78 HSD17B10 (0.51) HSD17B10LMNAL3MBTL1CYP2C9CYP3A4
SCHEMBL30088482 0.72 GAA (0.47) AKR1C3KDM4EALDH1A1HTTHPGD
SCHEMBL23832380 0.72 GAA (0.47) AKR1C3KDM4EALDH1A1HTTHPGD
SCHEMBL30605786 0.71 HSD17B10 (0.76) HSD17B10LMNAL3MBTL1CYP2C9CYP3A4
SCHEMBL9485241 0.71 HSD17B10 (0.76) HSD17B10LMNAL3MBTL1CYP2C9CYP3A4
SCHEMBL3866085 0.70 HSD17B10 (0.59) HSD17B10LMNAL3MBTL1CYP2C9CYP3A4
SCHEMBL30168124 0.70 HSD17B10 (0.59) HSD17B10LMNAL3MBTL1CYP2C9CYP3A4
SCHEMBL23331022 0.69 HSD17B10 (0.38) HSD17B10L3MBTL1KDM4EALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159489-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2023-05-25 — — US disclosed
US-20230159489-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2023-05-25 — — US disclosed
US-20230159489-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2023-05-25 — — US disclosed
EP-4121426-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE Akebia Therapeutics Inc. (US) 2023-01-25 — — EP disclosed
CN-115515948-A PHD inhibitor compounds, compositions and uses 阿克比治疗有限公司 2022-12-23 — — CN disclosed
WO-2021188938-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2021-09-23 — — WO disclosed
WO-2021188938-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2021-09-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159489-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE HIF1AN, EGLN3, PHF20 HSD17B10 343/4885LMNA 4071/4885L3MBTL1 3421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback